Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-03-11
2008-03-11
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S117000, C544S350000, C514S249000
Reexamination Certificate
active
07342012
ABSTRACT:
The present invention relates to a compound of the following formula:or a pharmaceutically acceptable salt thereof. Also disclosed are compositions containing the compound and methods of preparing and using the compounds. The compounds of the invention are useful in treating αLβ2adhesion mediated conditions in a mammal.
REFERENCES:
patent: A-82875/87 (1988-06-01), None
patent: WO 98/39303 (1998-09-01), None
patent: WO 98/58947 (1998-12-01), None
patent: WO 99 010312 (1999-03-01), None
Chalmers (TiPS vol. 17, pp. 166-172 Apr. 1996).
Dyatkin, Tetrahedron Letters, vol. 38, No. 12, pp. 2065-2066 (1997).
Kelly et al., J. Immunol., vol. 163, No. 10, pp. 5173-5177 (1999).
Bianco et al., J. Org. Chem., vol. 65, No. 7, pp. 2179-2187 (2000).
Chalmers (TiPS vol. 17, pp. 166-172 Apr. 1996).
Furth Paul
Griffith Ronald C.
Morningstar Marshall
Sircar Ila
Smith Nicholas
Birch & Stewart Kolasch & Birch, LLP
Habte Kahsay
Mitsubishi Tanabe Pharma Corporation
LandOfFree
Inhibitors of α L β 2 mediated cell adhesion does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of α L β 2 mediated cell adhesion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of α L β 2 mediated cell adhesion will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2797483